These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33336850)

  • 1. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
    Andersen G; Meiffren G; Famulla S; Heise T; Ranson A; Seroussi C; Eloy R; Gaudier M; Charvet R; Chan YP; Soula O; DeVries JH
    Diabetes Obes Metab; 2021 Apr; 23(4):961-970. PubMed ID: 33336850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.
    Andersen G; Eloy R; Famulla S; Heise T; Meiffren G; Seroussi C; Gaudier M; Mégret C; Chan YP; Soula O; Riddle M
    Diabetes Obes Metab; 2023 May; 25(5):1241-1248. PubMed ID: 36633505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
    Chase HP; Lutz K; Pencek R; Zhang B; Porter L
    J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.
    Andersen G; Eloy R; Heise T; Gaudier M; Mégret C; Seroussi C; Chan YP; Soula O; Riddle M; DeVries JH
    Diabetes Obes Metab; 2024 Oct; 26(10):4639-4645. PubMed ID: 39109464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.
    Ramkissoon CM; Aufderheide B; Bequette BW; Palerm CC
    J Diabetes Sci Technol; 2014 May; 8(3):529-42. PubMed ID: 24876617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
    Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
    Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.
    Hassan K; Heptulla RA
    Pediatr Diabetes; 2009 Jun; 10(4):264-8. PubMed ID: 19140902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
    Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
    Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
    McVey E; Hirsch L; Sutter DE; Kapitza C; Dellweg S; Clair J; Rebrin K; Judge K; Pettis RJ
    J Diabetes Sci Technol; 2012 Jul; 6(4):743-54. PubMed ID: 22920798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
    Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
    Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats.
    Maikawa CL; Chen PC; Vuong ET; Nguyen LT; Mann JL; d'Aquino AI; Lal RA; Maahs DM; Buckingham BA; Appel EA
    Adv Sci (Weinh); 2021 Nov; 8(21):e2101575. PubMed ID: 34499434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
    Weinzimer SA; Sherr JL; Cengiz E; Kim G; Ruiz JL; Carria L; Voskanyan G; Roy A; Tamborlane WV
    Diabetes Care; 2012 Oct; 35(10):1994-9. PubMed ID: 22815298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
    Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
    Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
    Leohr J; Kazda C; Liu R; Reddy S; Dellva MA; Matzopoulos M; Loh MT; Hardy T; Klein O; Kapitza C
    Diabetes Obes Metab; 2022 Feb; 24(2):187-195. PubMed ID: 34605142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.